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Introduction
Type I interferons (IFN-I) are critical for controlling virus infec-
tions (1, 2), but they also contribute to impaired host immunity and 
virus persistence (3, 4). The precise role of IFN-I during chronic 
HIV-1 infection remains unclear (5, 6). HIV-1 infection induces 
widespread expression of IFN-I and IFN-stimulated genes (ISGs) 
(7, 8). It has been reported that IFN-I can suppress HIV-1 replica-
tion in vitro (5), and the major anti–HIV-1 restriction factors are 
encoded by ISGs (5). In addition, IFN-I has been shown to inhibit 
early HIV-1 infection in humanized mice (hu-mice) (9) and SIV 
infection in rhesus macaques in vivo (10). These observations sug-
gest that a robust IFN-I response helps to control or limit initial 
HIV-1 and SIV infection.
IFN-I has also been implicated in the immunopathogenesis of 
AIDS during chronic HIV-1 infection (5, 6). Studies using nonhu-
man primate models have documented that sustained IFN-I sig-
naling is associated with pathogenic SIV infection (11–14). IFN-I is 
induced during the acute phase of SIV infection in both pathogenic 
(rhesus macaques or pigtail macaques) and nonpathogenic hosts 
(African green monkeys or sooty mangabeys). However, compared 
with the nonpathogenic natural SIV infection, pathogenic SIV 
infection leads to AIDS development, associated with sustained 
IFN-I signaling (11–14). Furthermore, studies in HIV-1–infected 
patients indicate that expression of IFN-I and ISGs is correlated 
with a higher level of viral load, enhanced hyperimmune activa-
tion, and faster disease progression (8, 15–17). Using the mouse 
model of lymphocytic choriomeningitis virus persistent infection, 
it is reported that blocking of IFN-I signaling by IFNAR antibody 
can reverse immune suppression, restore lymphoid architecture, 
and accelerate clearance of the virus (3, 4).
Administration of exogenous IFN-α can lower HIV-1 burden 
in HIV-1–infected patients but fail to show a significant benefit in 
HIV-1 disease progression (6). Interestingly, recent studies report 
that the administration of IFN-α in HIV-1–monoinfected patients 
or patients coinfected with HIV-1 and hepatitis C virus (HCV) 
results in reduction of cell-associated viral RNA and DNA in the 
blood (18–21). However, other studies in HIV-1–infected patients 
indicate that persistent expression of ISGs is correlated with high-
er viral load, enhanced hyperimmune activation, and faster dis-
ease progression (8, 15–17). In addition, administration of IFN-α 
to patients also leads to a decrease in CD4 T cell count (18, 21) 
and enhanced CD8 T cell activation (22) in the blood. Moreover, 
despite efficient suppression of HIV-1 replication with combined 
antiretroviral therapy (cART), abnormally elevated IFN-I signal-
ing persists in some patients even under extensive cART (23, 24), 
which may impede the reversion of hyperimmune activation and 
immune recovery in those immune nonresponder patients (25). 
Despite the efficient suppression of HIV-1 replication that can be achieved with combined antiretroviral therapy (cART), low 
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suggest that blocking IFNAR will provide a novel strategy to 
enhance immune recovery and to reduce HIV-1 reservoirs in those 
patients with sustained IFN-I signaling during suppressive cART.
Results
cART efficiently suppresses HIV-1 replication but fails to clear HIV-1 
reservoirs in hu-mice, correlated with low levels of ISG expression. To 
functionally define the role of IFN-I in HIV-1 persistent infection 
These reports highlight that IFN-I may play important but com-
plex roles in HIV-1 persistent infection and pathogenesis.
In the present study, we developed an antibody against human 
IFN-α/β receptor 1 (α-IFNAR1) to specifically block IFN-I signal-
ing. We found that IFNAR blockade during persistent HIV-1 infec-
tion reversed HIV-1–induced immune hyperactivation, rescued 
anti–HIV-1 immune responses, and reduced the size of HIV-1 res-
ervoirs in lymphoid tissues in the presence of cART. Our results 
Figure 1. cART efficiently inhibits HIV-1 replication but fails to reverse inflammation and clear HIV-1 reservoirs in hu-mice. (A and B) Hu-mice infected 
with HIV-1 were treated with cART from 4.5 to 11.5 weeks postinfection (wpi). (A) HIV-1 RNA levels in the plasma of HIV-1–infected (n = 3) and HIV-1–infect-
ed, cART-treated mice (n = 7) at indicated time points. (B) Percentage of p24+ CD4 T cells was determined by FACS. Shown are representative data of 3 
independent experiments (mock, n = 9; HIV-1, n = 9; HIV-1+cART, n = 15 in total) from n = 4 (mock), n = 3 (HIV-1), or n = 7 (HIV-1+cART) hu-mice per group. (C) 
Hu-mice infected with HIV-1 were treated with cART from 4 to 10 wpi. Relative mRNA levels of OAS1 and IRF7 in PBMCs are shown at indicated time points. 
Unpaired, 2-tailed Student’s t test was performed to compare between mock and HIV-1+cART group at each single time point. *P < 0.05, **P < 0.01. Shown 
are combined data from 2 independent experiments with mean values ± SEM (mock, n = 7; HIV-1, n = 7; HIV-1+cART, n = 8). (D) Cell-associated HIV-1 DNA and 
relative level of cell-associated HIV-1 RNA to human CD4 mRNA in human cells from spleen were quantified by PCR. (E) Replication-competent HIV-1 viruses 
from spleen were detected by the quantitative virus outgrowth assay. Shown are representative data (D and E) from n = 4 (mock), n = 4 (HIV-1), and n = 4 
(HIV-1+cART) hu-mice per group of 2 independent experiments. ***P < 0.001. One-way ANOVA and Bonferroni’s post hoc test was performed. (F) Hu-mice 
infected with HIV-1 were treated with cART from 4 to 10 wpi. cART was discontinued at week 10. HIV-1 RNA levels in the plasma of each mouse are shown. 
The broken horizontal line in F indicates the limit of detection of the assay.
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significantly rescued the number of human T cells and total 
human leukocytes (Figure 2C and Supplemental Figure 5), it only 
slightly decreased the expression level of CD38/HLA-DR (Figure 
2, D and E) and Ki67 on T cells (Figure 2, F and G). Both CD8 and 
CD4 T cells from cART-treated hu-mice still expressed signifi-
cantly higher levels of activation (Figure 2, D and E) and prolifer-
ation (Figure 2, F and G) markers in comparison with uninfected 
hu-mice. Interestingly, IFNAR blockade significantly reversed 
aberrant CD8 T cell activation and proliferation in the presence of 
cART (Figure 2, D–G).
IFNAR blockade reverses the exhaustion phenotype of human T 
cells and restores anti–HIV-1 T cell function. Despite successful viral 
inhibition by cART, T cells from patients with poor immune recon-
stitution sustained higher PD-1 expression (32). We therefore 
investigated whether IFNAR blockade could reverse expression of 
PD-1 and other exhaustion markers and rescue HIV-1–specific T 
cell function in the presence of cART. HIV-1 persistent infection in 
hu-mice induced both PD-1 and TIM-3 expression on CD8 T cells 
(Figure 3, A and B). We found that cART alone failed to significant-
ly reduce the expression of PD-1 and TIM-3 (Figure 3, A and B). 
Interestingly, IFNAR blockade combined with cART completely 
reduced expression of PD-1 and TIM-3 on CD8 T cells (Figure 
3, A and B). Whole transcriptome sequencing of purified human 
CD8 T cells revealed that cART plus IFNAR blockade also signifi-
cantly reduced the expression of other T cell exhaustion markers 
including CD160, TIGIT (T cell immunoreceptor with Ig and ITIM 
domains), and BATF (basic leucine transcription factor, ATF-like) 
(Figure 3C and ref. 33).
We further determined the function of HIV-1–specific T cells 
after IFNAR blockade. When stimulated with HIV-1 Gag peptide 
pools ex vivo, both CD8 and CD4 T cells from hu-mice with cART 
and IFNAR blockade (but not cART alone) produced significant-
ly higher levels of IFN-γ and IL-2 (Figure 3, D and E, and Supple-
mental Figure 6), indicating that IFNAR blockade also rescued the 
function of HIV-1–specific T cell responses. Taken together, these 
results indicate that, in the presence of cART, IFNAR blockade can 
reverse aberrant immune activation and T cell exhaustion and res-
cue anti–HIV-1 immune responses.
IFNAR blockade during cART reduces cART-resistant HIV-1 
reservoirs. The administration of cART cannot achieve HIV-1 
eradication, and virus rebounds quickly after cART discontinu-
ation, owing to the persistence of HIV-1 reservoirs during cART 
(34, 35). It was demonstrated that adaptive immune response 
contributes to the control of cART-resistant reservoirs (36, 37). 
Thus the improvement of anti–HIV-1 adaptive immune response 
by therapeutic vaccine or by other immune modulators has been 
proposed as an immunological strategy for HIV cure (38, 39). We 
postulated that the reversal of immune hyperactivation and the 
induction of elevated anti–HIV-1 T cell response by blocking of 
IFNAR might reduce the size of the cART-resistant HIV-1 reser-
voir and control HIV-1 rebound after cART cessation. We treat-
ed HIV-1–infected hu-mice that were fully cART-suppressed 
with α-IFNAR1 mAb for 3 weeks from 7 to 10 weeks postinfec-
tion (Figure 4A). Interestingly, IFNAR blockade, in the presence 
of cART, led to low blips of HIV-1 replication, which returned to 
undetectable levels after α-IFNAR1 mAb treatment was stopped 
(Figure 4A). Thus, IFNAR blockade induced activation of HIV-1 
and pathogenesis, we used humanized mice with a functional 
human immune system (hu-mice) for modeling HIV-1 infection 
and immunopathogenesis (26, 27). We and others have previously 
reported that persistent HIV-1 infection in hu-mice led to induc-
tion of IFN-I signaling, CD4 T cell depletion, aberrant immune 
activation, and expression of the exhaustion marker PD-1 on T 
cells (27–29). As in human patients, cART can efficiently inhib-
it HIV-1 replication in hu-mice (30, 31). We found that plasma 
viremia decreased to undetectable levels (<400 genome copies/
ml) in all HIV-infected hu-mice within 3 weeks after cART treat-
ment (Figure 1A). HIV-1 replication in lymphoid organs was also 
effectively inhibited by cART (Figure 1B). However, as observed 
in some patients (23, 24), cART failed to completely reduce ISG 
expression in HIV-1–infected mice to the level of uninfected 
hu-mice (Figure 1C). HIV-1 reservoirs, measured by cell-associ-
ated HIV-1 DNA and RNA (Figure 1D), and cells with infectious 
HIV-1 (Figure 1E), were still detectable in lymphoid organs of 
cART-treated hu-mice. As in cART-treated patients, HIV-1 res-
ervoirs persisted stably and virus rebounded rapidly after cART 
cessation (Figure 1F).
IFNAR blockade during cART-suppressed HIV-1 infection revers-
es aberrant immune activation. It is reported that abnormally ele-
vated levels of IFN-I signaling and ISG expression persist in some 
patients even under extensive cART (23, 24), which may impede 
immune recovery and foster viral persistence (6, 25). We hypothe-
sized that IFNAR blockade in the presence of cART would reverse 
hyperimmune or inflammatory activation and facilitate recovery 
of functional anti–HIV-1 adaptive immune responses, thereby 
enabling control of cART-resistant HIV-1 reservoirs. To block 
IFN-I signaling in hu-mice, we developed a monoclonal antibody 
(mAb) against human IFN-α/β receptor 1 (α-IFNAR1) that specif-
ically binds to human IFNAR1 (Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI90745DS1) and inhibits human IFN-I activity (Supplemental 
Figure 1, B and C). The α-IFNAR1 mAb neither bound to mouse 
IFNAR1 (Supplemental Figure 2A) nor blocked mouse IFN-I activ-
ity in mouse cells (Supplemental Figure 2B). Furthermore, we 
showed that the α-IFNAR1 mAb effectively blocked ISG induction 
in vivo in response to the TLR7/8 agonist R848 (resiquimod) in 
hu-mice (Supplemental Figure 3). Treatment with α-IFNAR1 mAb 
alone affected neither the percentage nor the number of human 
leukocyte subsets (Supplemental Figure 4, A and B), and adminis-
tration of α-IFNAR1 mAb did not affect the expression of ISGs in 
splenocytes in hu-mice (Supplemental Figure 4C).
We then analyzed the effect of IFNAR blockade on T cell 
activation and functions in the presence of cART treatment in 
HIV-1–infected hu-mice. We treated HIV-1–infected hu-mice that 
were fully cART-suppressed with α-IFNAR1 mAb for 3 weeks from 
7 to 10 weeks postinfection (Figure 2A). As in some cART-treat-
ed human patients (23, 24), cART failed to completely suppress 
expression of ISGs (Figure 1C and Figure 2B). In contrast, IFNAR 
blockade efficiently suppressed HIV-induced ISG expression in 
cART-treated hu-mice (Figure 2B and Supplemental Figure 4A). 
HIV-1 persistent infection in hu-mice also induced T cell deple-
tion, hyperimmune activation, and proliferation as indicated by 
the expression of the activation marker CD38/HLA-DR and the 
proliferation marker Ki67 (Figure 2, C–E). Although cART alone 
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IFNAR blockade reduced cell-associated HIV-1 DNA 14-fold in 
the spleen and 4.4-fold in the bone marrow (Figure 4B). Cell-as-
sociated HIV-1 RNA was also reduced in both spleen (17.7-fold) 
and bone marrow (4.4-fold) (Figure 4C). More importantly and 
consistently, IFNAR blockade significantly reduced the size of 
replication-competent HIV-1 reservoirs measured by quantita-
tive virus outgrowth assay (Figure 4D).
reservoirs. We speculated that the increase of anti–HIV-1 T cell 
immune responses by IFNAR blockade would eliminate or con-
trol the HIV-1–expressing cells and finally reduce HIV-1 reser-
voirs. We next analyzed the HIV-1 reservoir size in lymphoid 
organs 2 weeks after IFNAR blockade. We measured cell-asso-
ciated HIV-1 DNA and RNA by PCR, and replication-competent 
HIV-1 by the quantitative virus outgrowth assay. We found that 
Figure 2. IFNAR blockade during cART-suppressed HIV-1 infection completely reverses aberrant immune activation. (A) Schematic diagram of the 
experimental design. Hu-mice infected with HIV-1 were treated with cART from 4 to 12 wpi. From 7 to 10 wpi, the cART-treated mice were injected with 
α-IFNAR1 antibody or isotype control mIgG2a antibody twice a week. (B) Relative mRNA levels of OAS1 and IRF7 in PBMCs at 9 wpi. (C) Mice were sacri-
ficed at 12 wpi. Summarized data show numbers of human CD8 and CD4 T cells in spleens. (D) Representative dot plots show percentage HLA-DR+CD38+ 
of CD8 T cells from spleens. (E) Summarized data show percentage HLA-DR+CD38+ of CD8 and CD4 T cells from spleens. (F) Representative dot plots show 
percentage Ki67+ of CD8 T cells from spleens. (G) Summarized data show percentage Ki67+ of CD8 and CD4 T cells from spleens. Shown are combined data 
from 2 independent experiments with mean values ± SEM (mock, n = 7; HIV-1, n = 7; HIV-1+cART+mIgG2a, n = 8; HIV-1+cART+α-IFNAR1, n = 8). *P < 0.05, 
**P < 0.01, ***P < 0.001, by 1-way ANOVA and Bonferroni’s post hoc test.
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level between the 2 treatment groups (Figure 5B and Table 1). 
Based on the findings above, we conclude that IFNAR blockade 
reduced cART-resistant HIV-1 reservoirs and significantly con-
trolled HIV-1 rebound after cART cessation.
Discussion
The contribution of IFN-I signaling to HIV-1 persistence during 
chronic infection is not clearly defined (5, 6). Using hu-mice that 
support HIV-1 persistent infection, we showed that cART effi-
ciently inhibited HIV-1 replication and rescued T cell number in 
hu-mice with persistent HIV-1 infection. However, low levels of 
ISG expression, aberrant immune activation, T cell exhaustion, 
and HIV-1 reservoir persisted stably in cART-treated hu-mice. 
We demonstrated that IFNAR blockade in cART-treated hu-mice 
reversed T cell hyperimmune activation, rescued anti–HIV-1 T cell 
immunity, and reduced the size of HIV-1 reservoirs.
Despite efficient suppression of HIV-1 replication with cART, 
abnormally elevated IFN-I signaling persists in some individuals, 
which may impede immune recovery and foster viral persistence 
(23–25). We found here that in hu-mice persistently infected with 
HIV-1, cART efficiently inhibited viral replication, but failed to 
completely reverse elevated ISG expression and T cell immune 
IFNAR blockade during cART delays HIV-1 rebound after cART 
cessation. Finally, we analyzed the effect of IFNAR blockade on 
HIV-1 rebound after cART discontinuation. Hu-mice with per-
sistent HIV-1 infection received cART, followed by 5 injections 
of α-IFNAR1 mAb after full suppression of HIV-1 (Figure 5A). 
We stopped cART 2.5 weeks after the last α-IFNAR1 mAb injec-
tion and monitored virus rebound after cART discontinuation 
(Figure 5A). One week after cART cessation, HIV-1 rebounded 
in 56% (10/18) of the control-treated hu-mice, but in none of the 
hu-mice treated with IFNAR1 blockade (Figure 5, B and C, and 
Table 1). By the second week, 89% (16/18) of the control-treat-
ed hu-mice became HIV-1–positive while only 27% (3/11) of 
α-IFNAR1 mAb–treated hu-mice showed detectable viremia in 
the blood (Figure 5, B and C, and Table 1). We also found that 
cell-associated HIV-1 DNA and RNA in peripheral blood mono-
nuclear cells (PBMCs) was significantly lower in the α-IFNAR1 
mAb–treated group than in the control antibody–treated group 
(Figure 5D). By the third week, HIV-1 rebounded in all hu-mice 
(18/18) in the cART-only group and rebounded in 73% (8/11) 
of the cART plus IFNAR blockade hu-mice (Figure 5, B and C, 
and Table 1). The viral load in those hu-mice with rebounded 
HIV-1 at the third week after cART cessation reached the same 
Figure 3. IFNAR blockade during cART-suppressed HIV-1 infection reverses the exhaustion phenotype of CD8 T cells and restores anti–HIV-1 T cell 
function. Hu-mice were treated as in Figure 2. (A) Representative dot plots show percentage PD-1+ and TIM-3+ of CD8 T cells from spleens. (B) Summarized 
data show percentage PD-1+ and TIM-3+ of CD8 T cells from spleens. (C) RNA sequencing was performed with purified CD8 T cells from spleens. Shown is 
expression of CD160, TIGIT, and BATF in CD8 T cells from mock-treated (n = 2), HIV-1+cART+mIgG2a–treated (n = 3), and HIV-1+cART+α-IFNAR1–treated (n 
= 3) hu-mice. Transcripts per kilobase million (TPM) indicates the relative abundance of transcripts. Unpaired, 2-tailed Student’s t test was performed to 
compare between groups (C). (D and E) Splenocytes were stimulated ex vivo with HIV-1 Gag peptide pools for 8 hours (Brefeldin A added at 3 hours) fol-
lowed by intracellular cytokine staining. Representative dot plots (D) and summarized data (E) show percentages of IFN-γ– and IL-2–producing CD8 T cells. 
Shown are combined data from 2 independent experiments (A, B, D, and E) with mean values ± SEM (mock, n = 7; HIV-1, n = 7; HIV-1+cART+mIgG2a,  
n = 8; HIV-1+cART+α-IFNAR1, n = 8). *P < 0.05, **P < 0.01, ***P < 0.001, by 1-way ANOVA and Bonferroni’s post hoc test.
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activation and exhaustion. This model thus partially recapitu-
lates the phenotype of those immune nonresponder patients. We 
showed that blocking IFN-I signaling by using our newly devel-
oped anti-IFNAR1 mAb completely inhibited ISG expression, 
reversed T cell immune activation and exhaustion, and rescued 
anti–HIV-1 T cell function. Our results agree with recent findings 
showing that persistent IFN-I signaling plays a detrimental role 
during chronic lymphocytic choriomeningitis virus infection and 
that blockade of IFN-I signaling by IFNAR antibody could reverse 
T cell exhaustion and enhance antiviral immune response (3, 4). 
The IFNAR blocking antibody will thus facilitate novel therapeu-
tic development aimed at those difficult-to-treat HIV-1–infected 
patients with sustained IFN-I signaling during cART (23, 24, 40).
HIV-1 reservoirs are refractory to antiretroviral therapies 
(ART) and remain the major barrier to curing HIV-1 (34, 35). We 
report here that IFNAR blockade transiently increased HIV-1 RNA 
in the blood (viral load “blipping”) during cART, indicating that 
IFN-I signaling contributed to the low replication or latency of the 
HIV-1 reservoirs. Multiple mechanisms may lead to the reduction 
of HIV-1 reservoir size after IFNAR blockade during cART. The 
rescued immune response could target the HIV-1 reservoirs with 
elevated gene expression and kill the reservoir cells. Other fac-
tors, including HIV-1–induced death of reservoir cells and reduced 
general T cell activation and proliferation, after IFNAR blockade 
may also contribute to the reduction of HIV-1 reservoir size. The 
underlying mechanism of reservoir reduction by IFNAR blockade 
will be further elucidated in the future. Therefore, blocking IFN-I 
signaling in cART-treated subjects may provide a novel therapeu-
tic approach for HIV-1 cure (38).
In a recent report, blocking IFN-I signaling with an antagonis-
tic IFN-α2 mutant (IFN-ant) with increased IFNAR2 binding but 
diminished IFNAR1 binding activity (41) during the acute phase of 
SIV infection (0–4 weeks postinfection) in rhesus monkeys led to 
elevated SIV replication and accelerated disease progression (10). 
Conversely, while preinfection IFN-α2a administration results 
in decreased SIV transmission, continued IFN-α2a treatment 
appears to induce IFN-I desensitization and decrease antiviral 
gene expression, resulting in increased SIV replication and accel-
erated CD4 T cell loss (10). This study has major differences from 
our studies in that IFN-I signaling is blocked (or desensitized) only 
during acute SIV infection. The higher levels of SIV infection prob-
ably lead to the accelerated disease progression during the late 
Figure 4. IFNAR blockade during cART reduces cART-resistant HIV-1 reservoirs. Hu-mice infected with HIV-1 were treated with cART from 4 to 12 wpi. 
From 7 to 10 wpi, the cART-treated mice were injected with α-IFNAR1 antibody or isotype control mIgG2a antibody. (A) HIV-1 RNA levels in the plasma. The 
broken horizontal line indicates the limit of detection (400 copies/ml). (B) Cell-associated HIV-1 DNA in human cells from spleen and bone marrow was 
quantified by PCR. (C) Relative levels of cell-associated HIV-1 RNA in human cells from spleens and bone marrow were quantified by PCR. (D) Replica-
tion-competent HIV-1 viruses from spleens were detected by the quantitative virus outgrowth assay. Shown are combined data from 2 independent experi-
ments with mean values ± SEM (mock, n = 7; HIV-1, n = 7; HIV-1+cART+mIgG2a, n = 8; HIV-1+cART+α-IFNAR1, n = 8). *P < 0.05, ***P < 0.001, by 1-way 
ANOVA and Bonferroni’s post hoc test.
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stage of infection, in the absence of IFN-I blocking. It is generally 
believed that persistent IFN signaling during chronic infection can 
lead to general immune suppression (42). Therefore, IFN-I signal-
ing is beneficial during the acute stage to inhibit or prevent virus 
infection but becomes harmful during the chronic stage of HIV-1 
infection. Blocking IFN-I signaling with either the IFNAR mAb or 
the antagonistic IFN-α2 mutant protein in rhesus monkeys with 
persistent SIV infection and cART will be of great interest to fur-
ther clarify these therapeutic strategies.
Several recent reports have shown that the administration of 
IFN-α in HIV-1–monoinfected or HIV-1/HCV–coinfected patients 
leads to reduction of cell-associated viral RNA and DNA in the 
blood cells of a subset of treated patients (18–21). The study by Liv-
io Azzoni et al. (18) reports that long-term administration of IFN-α 
during and after ART in HIV-1–infected patients leads to suppres-
sion of HIV-1 rebound in approximately 40% of patients, whose 
PBMC-associated HIV-1 DNA (after 12 weeks with IFN-α only but 
no ART) is lower in comparison with their PBMCs during ART 
alone when normalized to their CD4 T cell counts. However, HIV-
1 reservoirs (cell-associated DNA) were not significantly changed 
by IFN-α treatment during ART. The administration of IFN-α may 
induce the migration of activated CD4 T cells into lymphoid organs 
and subsequently reduction in the peripheral blood (43); thus the 
reduction may be due to the redistribution of HIV-1 reservoir cells 
to lymphoid organs induced by IFN-α. Interestingly, treatment of 
HIV-1/HCV–coinfected patients with IFN-α/ribavirin appears to 
lead to a significant reduction of both CD4 and CD8 T cells (18, 20, 
21), which is consistent with our previous finding that IFN-I con-
tributes to T cell depletion during chronic HIV-1 infection (28, 44). 
In addition, a low level of HIV-1 replication in the presence of cART 
may also contribute to the HIV-1 reservoir pool (45). High levels of 
exogenous IFN-I may inhibit the low-level HIV-1 replication as well 
as enhance anti-HIV immune responses (46). Therefore, IFN-I sig-
naling may play complex roles during the acute and chronic phases 
of HIV-1 infection, both inhibiting viral replication and fostering 
viral persistence by inducing immune dysfunction.
It is important to point out, however, that the human immu-
nity developed in hu-mice is not fully functional as found in 
immunocompetent hosts (26, 27). The restoration of anti–HIV-
1 T cell immune response by IFNAR blockade in hu-mice may 
not be robust enough to eliminate or fully control the HIV-1 res-
ervoir. Another concern is the xenoreactive graft-versus-host 
Figure 5. IFNAR blockade during cART delays HIV-1 rebound after cART cessation. (A) Schematic diagram of the experimental design. Hu-mice infected with HIV-1 
for 7–9 weeks were treated with cART. The mice were then injected with α-IFNAR1 mAb or isotype control mIgG2a antibody 5 times (twice a week) starting from 
week 4 after cART. cART was maintained for an additional 2.5 weeks after the last antibody treatment. Virus rebound was detected by PCR weekly after cART 
cessation. (B) Plasma HIV-1 viremia in mice treated with cART plus α-IFNAR1 mAb or control mIgG2a. The broken horizontal line indicates the detection limit. 
(C) Kinetic analysis of HIV-1 rebound after cART cessation. (D) Cell-associated HIV-1 DNA and RNA in PBMCs at 2 weeks after cART cessation. Shown are combined 
data of 3 independent experiments (B and C) (HIV-1+cART+mIgG2a, n = 18; HIV-1+cART+α-IFNAR1, n = 11) or 2 independent experiments (D) (HIV-1+cART+mIgG2a,  
n = 10; HIV-1+cART+α-IFNAR1, n = 7) with mean values ± SEM. *P < 0.05. Gehan-Breslow-Wilcoxon test (C) or unpaired, 2-tailed Student’s t test (D) was performed.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 7 6 jci.org   Volume 127   Number 1   January 2017
in hu-mice than in primate models or in humans. The findings 
reported here in hu-mice should accordingly be confirmed with 
the IFNAR blockade in SIV-infected and cART-treated monkey 
models before clinical testing in HIV-1 patients.
Methods
Construction of hu-mice. NRG (NOD Rag2–/– γc–/–) mice were obtained 
from the Jackson Laboratory. All mice were housed and bred in a spe-
cific pathogen–free environment. Humanized NRG mice with a func-
tional human immune system were generated by intrahepatic injection 
of newborn mice with human fetal liver–derived CD34+ hematopoiet-
ic progenitor cells as previously reported (28). Humanized BLT (bone 
marrow/liver/thymus) mice were generated as previously reported 
(50). Briefly, 6- to 8-week-old NRG mice were sublethally irradiated 
and anesthetized, and 1-mm3 fragments of human fetal thymus were 
implanted under the kidney capsule. CD34+ hematopoietic progeni-
tor cells purified from fetal liver of the same donor were injected i.v. 
within 3 hours. Human immune cell engraftment was detected by 
flow cytometry 12 weeks after transplantation. All animal studies were 
approved by the University of North Carolina IACUC (ID 14-100).
disease (GVHD) in hu-mice cotransplanted with both human 
hematopoietic stem cells (HSCs) and thymus fragments. GVHD 
could happen in some long-term–engrafted mice (6–8 months), 
although the use of hosts lacking the IL-2 common γ receptor 
chain (we used NOD Rag2–/– γc–/– [NRG] mice) delays the onset 
of diseases as reported (47). In our study, most of our experi-
ments were terminated around 5–6 months after human cell 
transplant. We did not detect significant GVHD symptoms such 
as conjunctivitis, alopecia, or wasting diseases in the hu-mice 
during the study (data not shown). Furthermore, we observed 
similar results when mice humanized with only human HSCs 
were used, which developed minimal GVHD even more than 9 
months after human HSC engraftment (47). Therefore, the key 
findings in this study are not significantly affected by GVHD. 
In addition, lymphoid structures such as B cell follicles, which 
have been identified as HIV-1 sanctuary sites for HIV-1 reservoir 
cells to escape from CD8 T cell–mediated killing in nonhuman 
primate models (48) and HIV-infected people (49), are not fully 
developed in our hu-mice. It is thus possible that HIV-infected 
cells may be more susceptible to CD8 T cell–mediated control 
Table 1. IFNAR blockade in the presence of cART delays HIV-1 rebound after cART cessation
Donor Mouse no. % of cells (preinfection) Treatment HIV-1 RNA in plasma (log10)
D
CD45A CD3B CD4C W0 W4 W6 W9 W10 W11 W12
1 1962 81.3 59.0 79.7 mIgG2a 5.0 ND ND ND ND ND 6.2
1 1964 74.7 68.9 82.1 mIgG2a 5.1 ND ND ND ND 5.4 6.6
1 1972 93.9 59.2 72.9 mIgG2a 4.7 ND ND ND 5.1 6.5 6.3
1 1973 95.5 54.0 73.5 mIgG2a 5.1 ND ND ND 3.6 5.8 5.6
1 1974 90.8 48.0 79.7 mIgG2a 4.6 ND ND ND 4.5 6.2 6.2
1 1975 74.9 54.2 72.2 mIgG2a 4.9 ND ND ND 4.9 5.4 6.7
1 1965 80.6 64.6 86.3 α-IFNAR1 5.2 ND 3.1 ND ND ND 5.9
1 1966 96.8 66.4 80.5 α-IFNAR1 5.0 ND 3.4 ND ND 7.1 7.2
1 1967 62.8 47.3 70.9 α-IFNAR1 5.1 ND 0.0 ND ND ND 6.1
2 1976 83.2 38.4 51.6 mIgG2a 5.5 ND ND ND ND 5.1 5.1
2 1978 88.1 39.6 55.2 mIgG2a 5.0 ND ND ND 3.2 5.5 5.7
2 1979 85.7 33.4 58.3 mIgG2a 5.0 ND ND ND 3.7 5.5 5.3
2 1980 86.4 33.6 58.3 mIgG2a 5.6 ND ND ND 2.9 5.7 5.6
2 1981 80.3 35.0 32.2 α-IFNAR1 5.4 ND 3.4 ND ND ND 5.1
2 1982 83.4 43.5 41.3 α-IFNAR1 5.5 ND ND ND ND ND ND
2 1984 69.4 32.2 39.4 α-IFNAR1 5.4 ND 3.0 ND ND ND ND
2 1985 77.1 29.8 57 α-IFNAR1 6.0 ND ND ND ND ND 5.3
3 2112 15.4 54.4 74.0 mIgG2a 4.8 ND ND ND ND ND 5.2
3 2113 20.9 45.6 75.6 mIgG2a 4.6 ND 2.7 ND 3.6 5.3 6.1
3 2114 21.6 43.8 80.0 mIgG2a 5.9 ND ND ND ND 4.1 7.0
3 2115 10.0 59.6 63.6 mIgG2a 5.5 ND ND ND ND 5.6 5.8
3 2176 38.1 20.6 56.9 mIgG2a 4.4 ND ND ND 4.0 4.3 4.9
3 2177 46.3 24.0 64.6 mIgG2a 4.4 ND ND ND 4.3 4.4 5.2
3 2178 44.5 26.1 60.5 mIgG2a 4.7 ND ND ND ND 4.3 5.6
3 2179 37.5 25.9 62.4 mIgG2a 4.5 ND ND ND ND 2.8 5.6
3 2124 22.5 27.5 70.1 α-IFNAR1 6.3 ND ND ND ND ND 4.7
3 2125 4.4 45.9 62.8 α-IFNAR1 4.8 ND ND ND ND ND ND
3 2128 15.1 37.9 68.9 α-IFNAR1 5.8 ND ND ND ND 5.5 4.7
3 2174 60.9 27.9 73.7 α-IFNAR1 5.9 ND ND ND ND 4.5 5.9
Hu-mice were treated as in Figure 5E. APercentage of human CD45+ of total cells in PBMCs. BPercentage of CD3+ from human CD45+ cells. CPercentage of 
CD4+ from CD3+ cells. DWeeks after cART treatment. ND, not detectable.
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ic primers for ISG15 (5′-CGCAGATCACCCAGAAGATCG-3′ and 
5′-TTCGTCGCATTTGTCCACCA-3′), OAS1 (5′-TGTCCAAGGTGG-
TAAAGGGTG-3′ and 5′-CCGGCGATTTAACTGATCCTG-3′), MX2 
(5′-CAGAGGCAGCGGAATCGTAA-3′ and 5′-TGAAGCTCTAGCTC-
GGTGTTC-3′), and IRF7 (5′-GCTGGACGTGACCATCATGTA-3′ 
and 5′-GGGCCGTATAGGAACGTGC-3′). mRNA from spleen of 
nonhumanized NRG mice treated with the TLR8 agonist R848 was 
used as control to test the human specificity of the primers. No signal 
was detected by real-time PCR when mRNA from spleen of nonhu-
manized NRG mice treated with R848 was used as control. The ISG 
expression levels were normalized to mRNA level of human CD45. 
The result was calculated as a fold change in gene expression relative 
to mock mice using the ΔΔCt method of analysis (51). Briefly, the fold 
change is calculated by 2–ΔΔCt. ΔΔCt = (Ct gene of interest – Ct internal 
control) sample of treated mouse – (Ct gene of interest – Ct internal 
control) sample of mock mouse.
Combination antiretroviral therapy. Food formulated with antiret-
roviral individual drug was prepared as reported with elevated dose 
modifications (30). In brief, tablets of emtricitabine and tenofovir 
disoproxil fumarate (Truvada; Gilead Sciences) and raltegravir (Isen-
tress; Merck) were crushed into fine powder and manufactured with 
TestDiet 5B1Q feed (Modified LabDiet 5058 with 0.12% amoxicillin) 
into half-inch irradiated pellets. Final concentrations of drugs in the 
food were 4,800 mg/kg raltegravir, 1,560 mg/kg tenofovir disoproxil, 
and 1,040 mg/kg emtricitabine. The estimated daily drug doses were 
768 mg/kg raltegravir, 250 mg/kg tenofovir disoproxil, and 166 mg/
kg emtricitabine.
Flow cytometry and cell sorting. For surface staining, single-cell sus-
pensions prepared from peripheral blood, spleen, or mesenteric lymph 
nodes of hu-mice were stained with surface markers and analyzed on 
a CyAn ADP flow cytometer (Dako). For intracellular staining, cells 
were first stained with surface markers, and then fixed and permea-
bilized with Cytofix/Cytoperm buffer (BD Biosciences), followed by 
intracellular staining. FITC-conjugated anti-human HLA-DR (L243), 
IFN-γ (4S.B3), PE-conjugated anti-human CD38 (HIT2), CD303 
(201A), PerCP/Cy5.5–conjugated anti-human CD4 (RPA-T4), PE/
Cy7–conjugated anti-human CD8 (HIT8a), PB-conjugated anti-hu-
man CD14 (M5E2), IL-2 (MQ1-17H12), BV421-conjugated anti-hu-
man PD-1 (EH12.2H7), APC-conjugated anti-human CD11c (Bu15), 
and APC/Cy7–conjugated anti-human CD45 (HI30) were purchased 
from Biolegend. FITC-conjugated anti–HIV-1 p24 was purchased from 
Beckman Coulter. PE-conjugated anti-human active caspase-3 (C92-
605) was purchased from BD Pharmingen. Pacific Orange–conjugat-
ed anti-mouse CD45 (30-F11), PE/Texas red–conjugated anti-human 
CD3 (7D6), CD19 (SJ25-C1), and LIVE/DEAD Fixable Yellow Dead 
Cell Stain Kit were purchased from Invitrogen. Data were analyzed 
using Summit 4.3 software (Dako).
For CD8 T cell sorting, after staining with viability dye and sur-
face markers (anti-hCD45, -mCD45, -hCD3, -hCD4, -hCD8, -hCD11c, 
-hCD14, -hCD123), CD8 T cells (hCD45+mCD45–hCD3+hCD8+hCD4–) 
were sorted on a BD FACSAria II using a 70-mm nozzle and collect-
ed into Falcon round-bottom polypropylene tubes containing RPMI 
1640/10% FBS. The purity of sorted CD8 T cells was above 99%.
T cell stimulation and intracellular cytokine staining. For nonspecif-
ic stimulation, splenocytes from hu-mice were stimulated ex vivo with 
PMA (phorbol 12-myristate 13-acetate) (50 ng/ml) and ionomycin (1 μM) 
(Sigma-Aldrich) for 4 hours in the presence of brefeldin A (Biolegend). 
HIV-1 infection of hu-mice. The R5 tropic strain of HIV-1 (JR-CSF) 
was generated by transfection of 293T cells with plasmid containing full-
length HIV-1 (JR-CSF) genome. Hu-mice with stable human leukocyte 
reconstitution were anesthetized and infected with HIV-1 (JR-CSF) (10 
ng p24 or 3,000 infectious units per mouse) through retro-orbital injec-
tion. Hu-mice infected with 293T supernatant were used as mock control 
groups. Both male and female mice were used for all the experiments.
Development of anti-IFNAR1 blocking antibody. The mouse cell line 
L-929 transfected with the human IFNAR1 (extracellular domain and 
transmembrane domain) expression plasmid mentioned was used as 
the immunogen for immunization. For each immunization, the WT 
BALB/c female mice were injected i.p. with 5,000,000 immunogen 
cells with 10 μg CpG-1826 as adjuvant. After 5 times immunization, 
the spleen cells were fused with the mouse myeloma cell line SP2/0. 
For screening of the clones that could secrete the IFNAR1 binding 
antibody by flow cytometry, 293T cells transfected with the human 
IFNAR1 expression plasmid were used. Briefly, the human IFNAR1 
expression 293T cell line was firstly incubated with the supernatant of 
the hybridoma, then incubated with the PE-labeled goat anti-mouse 
IgG secondary antibody. Then, an IFN-I reporter 293T cell line sta-
bly transfected with a mouse A2 promoter–driven EGFP was used to 
screen antibody clones that could block the human IFNAR1 signaling.
In vitro blocking assay. The IFN-I reporter 293T cell line or human 
PBMCs or mouse splenocytes were preincubated with antibodies 
for 1 hour in 37 celsius, and the human IFN-α2b or mouse IFN-α was 
added with a final concentration of 5 ng/ml. IFN-I reporter 293T 
cells were harvested and EGFP expression was analyzed by flow 
cytometry 24 hours later. The IFN activity after anti-human IFNAR1 
treatment relative to samples with IFN-α2a treatment only was cal-
culated. To detect expression of ISGs in human PBMCs or mouse 
splenocytes, cells were harvested 4–5 hours later for ISG detection 
by quantitative real-time PCR. The primers used for the quanti-
tative real-time PCR in the in vitro assay were as follows: human 
ISG15 (5′-CGCAGATCACCCAGAAGATCG-3′ and 5′-TTCGTCG-
CATTTGTCCACCA-3′), human MX2 (5′-CAGAGGCAGCGGAATC-
GTAA-3′ and 5′-TGAAGCTCTAGCTCGGTGTTC-3′), human EF1A 
(5′-ATATGGTTCCTGGCAAGCCC-3′ and 5′-GTGGGGTGGCAG-
GTATTAGG-3′), mouse Isg15 (5′-TGGTACAGAACTGCAGCGAG-3′ 
and 5′-AGCCAGAACTGGTCTTCGTG-3′), mouse Mx2 (5′-GTGGCA-
GAGGGAGAATGTCG-3′ and 5′-TAAAACAGCATAACCTTTTGC-
GA-3′), mouse Gapdh (5′-GAGCCAACGGGTCATCT-3′ and 5′-GAG-
GGGCCATCCACAGTCTT-3′).
In vivo IFNAR blocking antibody treatments. To confirm the in vivo 
neutralizing activity of α-IFNAR1 mAbs, hu-mice were treated i.p. with 
α-IFNAR1 mAb or mIgG2a as isotype control 6 hours before R848 
treatment. HIV-1–infected, cART-treated mice were treated i.p. with 
IFNAR1 blocking antibodies from 7 to 10 weeks postinfection twice a 
week with 400 μg/mouse at the first injection and 200 g/mouse for 
the following treatments. The same dose of mouse isotype IgG2a con-
trol was used in all experiments. Cohorts of mice were randomized 
into different treatment groups by level of HIV-1 RNA in plasma.
Quantification of mRNA expression in hu-mice by reverse transcrip-
tase PCR. RNA from PBMCs or whole splenocytes from hu-mice 
was isolated with the RNeasy Plus extraction kit (Qiagen) and con-
verted to cDNA by reverse transcription with random hexamers and 
SuperScript III First-Strand Synthesis (Invitrogen). cDNA was then 
subjected to quantitative real-time PCR using human gene-specif-
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using SMART Seq v4 Ultra Low RNA-Seq kit for 48 reactions (Clontech). 
A Nextera kit was used for library construction, and sequencing was 
performed on Illumina HiSeq2500v4 with paired-end sequencing for 
50 cycles. Sequencing data FASTQ files for samples were processed in 
Salmon workflow in a Linux server operating system to output gene-level 
abundance estimates and statistical inference as gene-level raw counts. 
Those raw counts for samples were input into the edgeR program (Bio-
conductor) for differential gene expression analysis.
Statistics. Statistical analyses were performed using GraphPad 
Prism 5.0 software (GraphPad Software). Experiments were analyzed by 
2-tailed Student’s t test, or by 1-way ANOVA and Bonferroni’s post hoc 
test or Gehan-Breslow-Wilcoxon test, according to the assumptions of 
the test, as indicated in the figure legends for each experiment. *P < 0.05, 
**P < 0.01, ***P < 0.001. All the data with error bars are presented as 
mean values ± SEM. A P value less than 0.05 was considered significant.
Study approval. Human fetal liver and thymus tissues (gestational 
age 16–20 weeks) were obtained from elective or medically indicated 
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with outpatient clinics (Advanced Bioscience Resources, Alameda, Cal-
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constitute human subjects research as defined under federal regulations 
[45 CFR 46.102 (d or f) and 21 CFR 56.102(c)(e)(l)]. All animal studies 
were approved by the University of North Carolina IACUC.
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For antigen-specific stimulation, splenocytes from hu-mice were stimu-
lated ex vivo with peptide pools (2 μg/ml for each peptide) for HIV-1 GAG 
protein [PepMix HIV (GAG) Ultra; JPT Innovation Peptide Solutions] for 
3 hours without brefeldin A and then 5 hours in the presence of brefel-
din A. Cells were then fixed and permeabilized with Cytofix/Cytoperm 
buffer (BD Biosciences), and intracellular staining was then performed.
HIV-1 genomic RNA detection in plasma. HIV-1 RNA was puri-
fied from the plasma with the QIAampkit Viral RNA Mini Kit. The 
RNA was then reverse-transcribed and quantitatively detected by 
real-time PCR using the TaqMan Fast Virus 1-Step PCR kit (Thermo 
Fisher Scientific). The primers used for detecting the HIV gag gene 
were 5′-GGTGCGAGAGCGTCAGTATTAAG-3′ and 5′-AGCTCCCT-
GCTTGCCCATA-3′. The probe (FAM-AAAATTCGGTTAAGGCCAG-
GGGGAAAGAA-QSY7) used for detection was ordered from Applied 
Biosystems, and the reactions were set up following the manufactur-
er’s guidelines and were run on the QuantStudio 6 Flex PCR system 
(Applied Biosystems). The detection limit of the real-time PCR reac-
tion is 4 copies per reaction. Accordingly, due to the relatively small 
volume of each bleeding in mice (around 50–100 μl total blood), the 
limit of detection of the assay is 400 copies/ml plasma. We set the copy 
numbers that were below the detectable limit as 1.
Cell-associated HIV-1 DNA detection. To measure total cell-asso-
ciated HIV-1 DNA, nucleic acid was extracted from spleen and bone 
marrow cells using the DNeasy mini kit (Qiagen). HIV-1 DNA was 
quantified by real-time PCR. DNA from serial dilutions of ACH2 cells, 
which contain 1 copy of HIV genome in each cell, was used to generate 
a standard curve.
Cell-associated HIV-1 RNA detection. To measure total cell-asso-
ciated HIV-1 RNA, nucleic acid was extracted from spleen or bone 
marrow cells using the RNeasy plus mini kit (Qiagen). HIV-1 RNA 
was detected as described above. The HIV-1 RNA expression levels 
were normalized to human CD4 mRNA (5′-GGGCTTCCTCCTC-
CAAGTCTT-3′ and CCGCTTCGAGACCTTTGC) controls, and the 
result was calculated as fold change in gene expression.
Viral outgrowth assay. Viral outgrowth assay was performed as 
reported (52). Serial dilutions of human cells from splenocytes of 
hu-mice (1 × 106, 2 × 105, 4 × 104 human cells) were stimulated with phy-
tohemagglutinin (2 μg/ml) and IL-2 (100 U/ml) for 24 hours. MOLT4/
CCR5 cells were added on day 2 to enhance the survival of the cultured 
cells as well as to support and facilitate further HIV-1 replication. Culture 
medium containing IL-2 (NIH AIDS Reagent Program; https://www.
aidsreagent.org/) and T cell growth factor (homemade as described in 
the standard protocol) was replaced on days 5 and 9. After 7 and 14 days 
of culture, supernatant from each well was harvested and HIV-1 reverse 
transcriptase quantitative PCR was performed to score viral outgrowth. 
Estimated frequencies of cells with replication-competent HIV-1 were 
calculated using limiting dilution analysis.
RNA sequencing. Purified human CD8 T cells from spleens of hu-mice 
as described above were used to prepare RNA. The cDNA was prepared 
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 7 9jci.org   Volume 127   Number 1   January 2017
human immunodeficiency virus type 1 infection, 
in contrast to more modest and delayed respons-
es in acute hepatitis B and C virus infections.  
J Virol. 2009;83(8):3719–3733.
 8. Hardy GA, et al. Interferon-α is the primary plas-
ma type-I IFN in HIV-1 infection and correlates 
with immune activation and disease markers. 
PLoS One. 2013;8(2):e56527.
 9. Lavender KJ, et al. Interferon α subtype-specific 
suppression of HIV-1 infection in vivo. J Virol. 
2016;90(13):6001–6013.
 10. Sandler NG, et al. Type I interferon respons-
es in rhesus macaques prevent SIV infec-
tion and slow disease progression. Nature. 
2014;511(7511):601–605.
 11. Jacquelin B, et al. Nonpathogenic SIV infection of 
African green monkeys induces a strong but rap-
idly controlled type I IFN response. J Clin Invest. 
2009;119(12):3544–3555.
 12. Bosinger SE, et al. Global genomic analysis 
reveals rapid control of a robust innate response 
in SIV-infected sooty mangabeys. J Clin Invest. 
2009;119(12):3556–3572.
 13. Harris LD, et al. Downregulation of robust acute 
type I interferon responses distinguishes nonpatho-
genic simian immunodeficiency virus (SIV) infec-
tion of natural hosts from pathogenic SIV infection 
of rhesus macaques. J Virol. 2010;84(15):7886–7891.
 14. Favre D, et al. Critical loss of the balance 
between Th17 and T regulatory cell popula-
tions in pathogenic SIV infection. PLoS Pathog. 
2009;5(2):e1000295.
 15. Rotger M, et al. Genome-wide mRNA expres-
sion correlates of viral control in CD4+ T-cells 
from HIV-1-infected individuals. PLoS Pathog. 
2010;6(2):e1000781.
 16. Hyrcza MD, et al. Distinct transcriptional 
profiles in ex vivo CD4+ and CD8+ T cells are 
established early in human immunodeficiency 
virus type 1 infection and are characterized by a 
chronic interferon response as well as extensive 
transcriptional changes in CD8+ T cells. J Virol. 
2007;81(7):3477–3486.
 17. Sedaghat AR, et al. Chronic CD4+ T-cell acti-
vation and depletion in human immunodefi-
ciency virus type 1 infection: type I interferon- 
mediated disruption of T-cell dynamics. J Virol. 
2008;82(4):1870–1883.
 18. Azzoni L, et al. Pegylated interferon alfa-2a mono-
therapy results in suppression of HIV type 1 rep-
lication and decreased cell-associated HIV DNA 
integration. J Infect Dis. 2013;207(2):213–222.
 19. Sun H, et al. Hepatitis C therapy with interferon-α 
and ribavirin reduces CD4 T-cell-associated 
HIV-1 DNA in HIV-1/hepatitis C virus-coinfected 
patients. J Infect Dis. 2014;209(9):1315–1320.
 20. Jiao YM, et al. Hepatitis C therapy with interfer-
on-α and ribavirin reduces the CD4 cell count 
and the total, 2LTR circular and integrated HIV-1 
DNA in HIV/HCV co-infected patients. Antiviral 
Res. 2015;118:118–122.
 21. Morón-López S, et al. Short-term treatment with 
interferon alfa diminishes expression of HIV-1 
and reduces CD4+ T-cell activation in patients 
coinfected with HIV and hepatitis C virus and 
receiving antiretroviral therapy. J Infect Dis. 
2016;213(6):1008–1012.
 22. Manion M, et al. Interferon-α administration 
enhances CD8+ T cell activation in HIV infec-
tion. PLoS One. 2012;7(1):e30306.
 23. Fernandez S, et al. CD4+ T-cell deficiency in HIV 
patients responding to antiretroviral therapy is 
associated with increased expression of interfer-
on-stimulated genes in CD4+ T cells. J Infect Dis. 
2011;204(12):1927–1935.
 24. Dunham RM, et al. Discordance between periph-
eral and colonic markers of inflammation during 
suppressive ART. J Acquir Immune Defic Syndr. 
2014;65(2):133–141.
 25. Deeks SG. HIV infection, inflammation, 
immunosenescence, and aging. Annu Rev Med. 
2011;62:141–155.
 26. Shultz LD, Brehm MA, Garcia-Martinez JV, 
Greiner DL. Humanized mice for immune sys-
tem investigation: progress, promise and chal-
lenges. Nat Rev Immunol. 2012;12(11):786–798.
 27. Zhang L, Su L. HIV-1 immunopathogenesis in 
humanized mouse models. Cell Mol Immunol. 
2012;9(3):237–244.
 28. Li G, et al. Plasmacytoid dendritic cells suppress 
HIV-1 replication but contribute to HIV-1 induced 
immunopathogenesis in humanized mice. PLoS 
Pathog. 2014;10(7):e1004291.
 29. Seung E, Dudek TE, Allen TM, Freeman GJ, Lus-
ter AD, Tager AM. PD-1 blockade in chronically 
HIV-1-infected humanized mice suppresses viral 
loads. PLoS One. 2013;8(10):e77780.
 30. Halper-Stromberg A, et al. Broadly neutralizing 
antibodies and viral inducers decrease rebound 
from HIV-1 latent reservoirs in humanized mice. 
Cell. 2014;158(5):989–999.
 31. Choudhary SK, Archin NM, Cheema M, Dahl NP, 
Garcia JV, Margolis DM. Latent HIV-1 infection of 
resting CD4+ T cells in the humanized Rag2−/−γc−/− 
mouse. J Virol. 2012;86(1):114–120.
 32. Grabmeier-Pfistershammer K, Steinberger P, Rieg-
er A, Leitner J, Kohrgruber N. Identification of PD-1 
as a unique marker for failing immune reconstitu-
tion in HIV-1-infected patients on treatment.  
J Acquir Immune Defic Syndr. 2011;56(2):118–124.
 33. Wherry EJ, Kurachi M. Molecular and cellular 
insights into T cell exhaustion. Nat Rev Immunol. 
2015;15(8):486–499.
 34. Katlama C, et al. Barriers to a cure for HIV: new 
ways to target and eradicate HIV-1 reservoirs. 
Lancet. 2013;381(9883):2109–2117.
 35. Archin NM, Sung JM, Garrido C, Soriano-Sarabia 
N, Margolis DM. Eradicating HIV-1 infection: 
seeking to clear a persistent pathogen. Nat Rev 
Microbiol. 2014;12(11):750–764.
 36. Deng K, et al. Broad CTL response is required to 
clear latent HIV-1 due to dominance of escape 
mutations. Nature. 2015;517(7534):381–385.
 37. Shan L, et al. Stimulation of HIV-1-specific 
cytolytic T lymphocytes facilitates elimination 
of latent viral reservoir after virus reactivation. 
Immunity. 2012;36(3):491–501.
 38. Barouch DH, Deeks SG. Immunologic strategies 
for HIV-1 remission and eradication. Science. 
2014;345(6193):169–174.
 39. Siliciano RF. Opening Fronts in HIV Vaccine 
Development: Targeting reservoirs to clear and 
cure. Nat Med. 2014;20(5):480–481.
 40. Zhang Z, et al. Safety and immunological 
responses to human mesenchymal stem cell ther-
apy in difficult-to-treat HIV-1-infected patients. 
AIDS. 2013;27(8):1283–1293.
 41. Levin D, et al. Multifaceted activities of type I 
interferon are revealed by a receptor antagonist. 
Sci Signal. 2014;7(327):ra50.
 42. Crouse J, Kalinke U, Oxenius A. Regulation of 
antiviral T cell responses by type I interferons. 
Nat Rev Immunol. 2015;15(4):231–242.
 43. Massanella M, et al. Changes in T-cell subsets in 
HIV-HCV-coinfected patients during pegylated 
interferon-α2a plus ribavirin treatment. Antivir 
Ther (Lond). 2010;15(3):333–342.
 44. Zhang Z, et al. Plasmacytoid dendritic cells pro-
mote HIV-1-induced group 3 innate lymphoid cell 
depletion. J Clin Invest. 2015;125(9):3692–3703.
 45. Lorenzo-Redondo R, et al. Persistent HIV-1 
replication maintains the tissue reservoir during 
therapy. Nature. 2016;530(7588):51–56.
 46. Tomescu C, Mavilio D, Montaner LJ. Lysis of 
HIV-1-infected autologous CD4+ primary T cells 
by interferon-α-activated NK cells requires NKp46 
and NKG2D. AIDS. 2015;29(14):1767–1773.
 47. Greenblatt MB, et al. Graft versus host disease in 
the bone marrow, liver and thymus humanized 
mouse model. PLoS One. 2012;7(9):e44664.
 48. Fukazawa Y, et al. B cell follicle sanctuary permits 
persistent productive simian immunodeficiency 
virus infection in elite controllers. Nat Med. 
2015;21(2):132–139.
 49. Perreau M, et al. Follicular helper T cells serve 
as the major CD4 T cell compartment for HIV-1 
infection, replication, and production. J Exp Med. 
2013;210(1):143–156.
 50. Namikawa R, Kaneshima H, Lieberman 
M, Weissman IL, McCune JM. Infection 
of the SCID-hu mouse by HIV-1. Science. 
1988;242(4886):1684–1686.
 51. Schmittgen TD, Livak KJ. Analyzing real-time 
PCR data by the comparative C(T) method. Nat 
Protoc. 2008;3(6):1101–1108.
 52. Laird GM, Rosenbloom DI, Lai J, Siliciano RF, 
Siliciano JD. Measuring the frequency of latent 
HIV-1 in resting CD4+ T cells using a limiting 
dilution coculture assay. Methods Mol Biol. 
2016;1354:239–253.
